About ADMA Biologics (NASDAQ:ADMA)
ADMA Biologics, Inc. is a late-stage biopharmaceutical company that develops, manufactures and intends to market specialty plasma-based biologics for the treatment and prevention of infectious diseases. The Company is engaged in the development and commercialization of human plasma and plasma-derived therapeutics. Its segments include Plasma Collection Centers, which includes its operations in Georgia; Research and Development, which includes its plasma development operations in New Jersey, and Corporate. Its targeted patient populations are immune-compromised individuals suffering from an underlying immune deficiency disorder or may be immune-suppressed for medical reasons. Its product candidates are intended to be used by physician specialists focused on caring for immune-compromised patients at risk of contracting infectious diseases. Its intravenous immunoglobulin product candidate, RI-002, is intended for the treatment of primary immune deficiency disease.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Bio Therapeutic Drugs
- Sub-Industry: N/A
- Symbol: NASDAQ:ADMA
- CUSIP: N/A
- Web: www.admabiologics.com
Capitalization:- Market Cap: $71.19 million
- Outstanding Shares: 12,886,000
Average Prices:- 50 Day Moving Avg: $3.23
- 200 Day Moving Avg: $3.61
- 52 Week Range: $2.67 - $6.88
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -1.46
- P/E Growth: 0.00
Sales & Book Value:- Annual Revenue: $12.29 million
- Price / Sales: 3.00
- Book Value: ($0.35) per share
- Price / Book: -8.17
Profitability:- EBITDA: ($17,610,000.00)
- Net Margins: -198.99%
- Return on Equity: -791.24%
- Return on Assets: -63.60%
Debt:- Debt-to-Equity Ratio: 0.87%
- Current Ratio: 2.83%
- Quick Ratio: 1.99%
Misc:- Average Volume: 36,551 shs.
- Beta: 2.48
- Short Ratio: 0.47
Frequently Asked Questions for ADMA Biologics (NASDAQ:ADMA)
What is ADMA Biologics' stock symbol?
ADMA Biologics trades on the NASDAQ under the ticker symbol "ADMA."
How were ADMA Biologics' earnings last quarter?
ADMA Biologics Inc (NASDAQ:ADMA) issued its earnings results on Friday, August, 11th. The company reported ($0.55) EPS for the quarter, missing the consensus estimate of ($0.26) by $0.29. The firm earned $3.40 million during the quarter, compared to analysts' expectations of $3.52 million. ADMA Biologics had a negative return on equity of 791.24% and a negative net margin of 198.99%. View ADMA Biologics' Earnings History.
When will ADMA Biologics make its next earnings announcement?
Where is ADMA Biologics' stock going? Where will ADMA Biologics' stock price be in 2017?
1 brokers have issued 1-year price objectives for ADMA Biologics' shares. Their predictions range from $13.00 to $13.00. On average, they anticipate ADMA Biologics' share price to reach $13.00 in the next year. View Analyst Ratings for ADMA Biologics.
Who are some of ADMA Biologics' key competitors?
Some companies that are related to ADMA Biologics include Cellular Biomedicine Group (CBMG), Verona Pharma Plc (VRP), ImmuPharma PLC (IMM), MaxCyte (MXCT), Axsome Therapeutics (AXSM), Aldeyra Therapeutics (ALDX), Synthetic Biologics (SYN), Summit Therapeutics PLC (SUMM), ProQR Therapeutics N.V. (PRQR), Dicerna Pharmaceuticals (DRNA), Trevena (TRVN), Motif Bio PLC (MTFB), Cidara Therapeutics (CDTX), Otonomy (OTIC), Zafgen (ZFGN), Gemphire Therapeutics (GEMP), Galmed Pharmaceuticals (GLMD) and Intec Pharma (NTEC).
Who are ADMA Biologics' key executives?
ADMA Biologics' management team includes the folowing people:
- Steven A. Elms, Chairman of the Board
- Adam S. Grossman, President, Chief Executive Officer, Director
- Jerrold B. Grossman D.P.S, Vice Chairman of the Board
- Brian Lenz, Chief Financial Officer
- James Mond M.D., Ph.D., Chief Scientific and Medical Officer
- Bernhard R. M. Ehmer, Director
- Bryant E. Fong, Independent Director
- Dov A. Goldstein M.D., Independent Director
- Lawrence P. Guiheen, Independent Director
- Eric I. Richman, Independent Director
How do I buy ADMA Biologics stock?
Shares of ADMA Biologics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is ADMA Biologics' stock price today?
One share of ADMA Biologics stock can currently be purchased for approximately $2.86.
MarketBeat Community Rating for ADMA Biologics (NASDAQ ADMA)MarketBeat's community ratings are surveys of what our community members think about ADMA Biologics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for ADMA Biologics (NASDAQ:ADMA) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 1 Buy Rating |
| Consensus Rating: | Buy (Score: 3.00) |
| Consensus Price Target: | $13.00 (354.55% upside) |
Consensus Price Target History for ADMA Biologics (NASDAQ:ADMA)
Analysts' Ratings History for ADMA Biologics (NASDAQ:ADMA)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 6/28/2017 | Maxim Group | Reiterated Rating | Buy | $13.00 | Medium |  |
| 8/1/2016 | Raymond James Financial, Inc. | Downgrade | Strong-Buy -> Market Perform | | N/A | |
(Data available from 10/20/2015 forward)
Earnings History for ADMA Biologics (NASDAQ:ADMA)Earnings History by Quarter for ADMA Biologics (NASDAQ ADMA)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 11/8/2017 | | ($0.43) | | | | | N/A | |
| 8/11/2017 | Q2 2017 | ($0.26) | ($0.55) | $3.52 million | $3.40 million | View | N/A | |
| 5/12/2017 | Q1 2017 | ($0.28) | ($0.51) | $3.35 million | $2.63 million | View | N/A | |
| 11/10/2016 | Q3 2016 | ($0.42) | ($0.34) | $2.32 million | $2.94 million | View | N/A | |
| 8/12/2016 | Q2 | ($0.39) | ($0.50) | $2.35 million | $2.27 million | View | N/A | |
| 5/13/2016 | Q1 | ($0.37) | ($0.43) | $2.48 million | $2.12 million | View | N/A | |
| 11/10/2015 | Q315 | ($0.39) | ($0.48) | $1.50 million | $1.85 million | View | N/A | |
| 8/11/2015 | Q215 | ($0.32) | ($0.37) | $1.50 million | $1.30 million | View | N/A | |
| 5/12/2015 | Q115 | ($0.32) | ($0.37) | $1.50 million | $1.50 million | View | N/A | |
| 3/9/2015 | Q4 2014 | ($0.38) | ($0.38) | $1.52 million | $1.41 million | View | N/A | |
| 11/10/2014 | Q3 2014 | ($0.37) | ($0.36) | | $1.37 million | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for ADMA Biologics (NASDAQ:ADMA)| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q2 2017 | 1 | ($0.30) | ($0.30) | ($0.30) |
| Q3 2017 | 1 | ($0.64) | ($0.64) | ($0.64) |
| Q4 2017 | 1 | ($0.63) | ($0.63) | ($0.63) |
(Data provided by Zacks Investment Research)
Dividend History for ADMA Biologics (NASDAQ:ADMA)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for ADMA Biologics (NASDAQ:ADMA)Insider Ownership Percentage: 60.44%
Institutional Ownership Percentage: 34.55%
Insider Trades by Quarter for ADMA Biologics (NASDAQ:ADMA)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 5/3/2016 | Adam S Grossman | CEO | Buy | 200,000 | $6.50 | $1,300,000.00 | |
| 5/3/2016 | Brian Lenz | CFO | Buy | 2,500 | $6.50 | $16,250.00 | |
| 5/3/2016 | James Mond | CMO | Buy | 770 | $6.50 | $5,005.00 | |
| 5/3/2016 | Jerrold B Grossman | Director | Buy | 45,769 | $6.50 | $297,498.50 | |
| 12/8/2015 | Adam S. Grossman | CEO | Buy | 500 | $9.00 | $4,500.00 | |
| 12/7/2015 | Jerrold B Grossman | Director | Buy | 500 | $9.01 | $4,505.00 | |
| 12/2/2015 | Adam S Grossman | CEO | Buy | 2,250 | $9.15 | $20,587.50 | |
| 12/2/2015 | Brian Lenz | CFO | Buy | 1,000 | $9.15 | $9,150.00 | |
| 12/2/2015 | Jerrold B Grossman | Director | Buy | 6,000 | $9.16 | $54,960.00 | |
| 12/1/2015 | Adam S Grossman | CEO | Buy | 1,800 | $9.17 | $16,506.00 | |
| 11/25/2015 | Adam S Grossman | CEO | Buy | 1,800 | $9.18 | $16,524.00 | |
| 11/20/2015 | Adam S Grossman | CEO | Buy | 3,861 | $9.21 | $35,559.81 | |
| 3/19/2015 | Adam S Grossman | CEO | Buy | 2,000 | $8.50 | $17,000.00 | |
| 3/17/2015 | Adam S Grossman | CEO | Buy | 5,500 | $7.98 | $43,890.00 | |
| 3/17/2015 | Jerrold B Grossman | Director | Buy | 500 | $8.01 | $4,005.00 | |
| 3/16/2015 | Adam S Grossman | CEO | Buy | 8,800 | $8.03 | $70,664.00 | |
| 3/16/2015 | James Mond | CMO | Buy | 1,250 | $8.02 | $10,025.00 | |
| 3/16/2015 | Lawrence P Guiheen | Director | Buy | 1,000 | $7.96 | $7,960.00 | |
| 3/13/2015 | Eric I Richman | Director | Buy | 3,500 | $7.88 | $27,580.00 | |
| 9/12/2014 | Adam S Grossman | CEO | Buy | 4,300 | $9.57 | $41,151.00 | |
| 8/22/2014 | Adam S Grossman | CEO | Buy | 1,000 | $9.50 | $9,500.00 | |
| 8/14/2014 | Adam S Grossman | CEO | Buy | 2,100 | $9.77 | $20,517.00 | |
| 6/18/2014 | Adam S Grossman | CEO | Buy | 1,875 | $9.59 | $17,981.25 | |
| 5/22/2014 | Adam S Grossman | CEO | Buy | 4,226 | $8.15 | $34,441.90 | |
| 5/15/2014 | Adam S Grossman | CEO | Buy | 13,400 | $7.50 | $100,500.00 | |
| 5/14/2014 | Brian Lenz | CFO | Buy | 1,000 | $7.50 | $7,500.00 | |
| 5/14/2014 | James Mond | CMO | Buy | 1,315 | $7.60 | $9,994.00 | |
| 12/10/2013 | Jerrold B Grossman | Director | Buy | 3,650 | $7.30 | $26,645.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for ADMA Biologics (NASDAQ:ADMA)
Latest Headlines for ADMA Biologics (NASDAQ:ADMA)
| Source: |
|
| Date | Headline |
|---|
 | BRIEF-Adma Biologics Inc files for offering of up to $28.75 million of common stock
www.reuters.com - October 11 at 9:02 PM |
| BRIEF-ADMA Biologics enters into credit agreement for up to $40 mln with affiliated entities of Marathon Asset Management
www.reuters.com - October 11 at 4:00 PM |
 | Marathon Asset Management and ADMA Biologics Complete $30 Million Debt Refinancing
finance.yahoo.com - October 11 at 4:00 PM |
 | $6.86 Million in Sales Expected for ADMA Biologics Inc (ADMA) This Quarter
www.americanbankingnews.com - October 8 at 1:28 AM |
| ETFs with exposure to ADMA Biologics, Inc. : September 28, 2017
finance.yahoo.com - October 2 at 3:16 PM |
 | ADMA Biologics (ADMA) Presents At Ladenburg Thalmann 2017 Healthcare Conference - Slideshow
seekingalpha.com - September 27 at 8:30 PM |
| ETFs with exposure to ADMA Biologics, Inc. : September 7, 2017
finance.yahoo.com - September 7 at 3:24 PM |
| ETFs with exposure to ADMA Biologics, Inc. : September 7, 2017
finance.yahoo.com - September 7 at 3:23 PM |
| ADMA Biologics, Inc. :ADMA-US: Earnings Analysis: Q2, 2017 By the Numbers : September 5, 2017
finance.yahoo.com - September 5 at 3:54 PM |
| -$0.51 Earnings Per Share Expected for ADMA Biologics Inc (ADMA) This Quarter
www.americanbankingnews.com - August 30 at 2:10 PM |
| ADMA: Second Quarter 2017 Financial Results and Corporate Update
finance.yahoo.com - August 28 at 3:37 PM |
| ADMA Biologics to Present at Upcoming Investor Conferences
finance.yahoo.com - August 23 at 3:27 PM |
| $6.81 Million in Sales Expected for ADMA Biologics Inc (ADMA) This Quarter
www.americanbankingnews.com - August 14 at 8:37 AM |
| ADMA Biologics Inc (NASDAQ:ADMA) Releases Earnings Results, Misses Expectations By $0.29 EPS
www.americanbankingnews.com - August 12 at 10:56 AM |
| ADMA Biologics Inc (ADMA) Expected to Post Earnings of -$0.42 Per Share
www.americanbankingnews.com - August 12 at 4:08 AM |
| ADMA Biologics Provides Corporate Update and Reports Second Quarter 2017 Financial Results
finance.yahoo.com - August 11 at 9:03 PM |
| Adma Biologics reports 2Q loss
finance.yahoo.com - August 11 at 9:03 PM |
| ADMA Biologics Inc (ADMA) to Release Quarterly Earnings on Thursday
www.americanbankingnews.com - August 3 at 7:00 AM |
| BRIEF-U.S. Patent and Trademark Office issues immunotehrapy patent to Adma Biologics
www.reuters.com - August 1 at 1:44 AM |
| ADMA Biologics Strengthens Patent Portfolio Through Newly Issued U.S. Patent for Immunotherapeutic Methods
finance.yahoo.com - July 31 at 8:43 PM |
 | At the Site of Germany’s Biggest World War II Battle, a Changing View of History
www.nytimes.com - July 19 at 1:58 AM |
 | Click to Bid: Feds Selling Big Denver Development Site Online
www.wsj.com - July 19 at 1:58 AM |
 | AP Explains: Korean border village, site for rivals' talks
www.foxnews.com - July 19 at 1:58 AM |
| Financial Comparison: Calithera Biosciences (CALA) versus ADMA Biologics (NASDAQ:ADMA)
www.americanbankingnews.com - July 18 at 10:30 AM |
| ETFs with exposure to ADMA Biologics, Inc. : July 13, 2017
finance.yahoo.com - July 13 at 4:07 PM |
| Maxim Group Reiterates Buy Rating for ADMA Biologics Inc (ADMA)
www.americanbankingnews.com - July 2 at 7:32 PM |
 | Form 8-K ADMA BIOLOGICS, INC. For: Jun 27
www.streetinsider.com - June 27 at 8:25 PM |
| BRIEF-Adma Biologics says approved 5 pct increases in annual cash bonuses to CEO, CFO among others
www.reuters.com - June 9 at 8:26 PM |
| ADMA Biologics (ADMA) Presents At Jefferies 2017 Global Healthcare Conference - Slideshow
seekingalpha.com - June 8 at 8:26 PM |
| BRIEF-Biotest sells US therapy business to Adma Biologics, Inc.
www.reuters.com - June 7 at 3:24 PM |
| BRIEF-ADMA Biologics Q1 loss per share $0.51
www.reuters.com - May 13 at 3:23 PM |
 | Biotest AG: Discussions regarding possible business combination
uk.finance.yahoo.com - March 29 at 8:27 PM |
 | Shareholder Alert: Monteverde & Associates PC Announces An Investigation Of ADMA Biologics, Inc. - ADMA - PR Newswire (press release)
www.prnewswire.com - March 28 at 8:02 AM |
| ADMA BIOLOGICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhi
biz.yahoo.com - February 24 at 6:19 PM |
| ADMA BIOLOGICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers
biz.yahoo.com - February 18 at 7:49 AM |
| Form 4 ADMA BIOLOGICS, INC. For: Feb 14 Filed by: LENZ BRIAN - StreetInsider.com
www.streetinsider.com - February 17 at 9:41 AM |
| Form 4 ADMA BIOLOGICS, INC. For: Feb 14 Filed by: Guiheen Lawrence P. - StreetInsider.com
www.streetinsider.com - February 17 at 9:41 AM |
| Blood Plasma Market 2017-2021 Key Regions Competitive Analysis
www.prnewswire.com - January 27 at 9:45 PM |
| ADMA Biologics (ADMA) to Acquire Assets from Biotest Pharmaceuticals
www.streetinsider.com - January 25 at 1:43 AM |
 | DGAP-Adhoc: Biotest AG: Biotest verkauft US-Therapiegeschäft an ... - FinanzNachrichten.de
www.finanznachrichten.de - January 24 at 1:25 AM |
| ADMA BIOLOGICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale of Equity Secu
biz.yahoo.com - January 23 at 8:24 PM |
ADMA Biologics (ADMA) Chart for Friday, October, 20, 2017
